SB2099, titled the "Restore Prescription Drugs Discount Act," would repeal the Robinson-Patman Act of 1936 in its entirety. The bill is very short and contains no additional policy framework, exceptions, or replacement provisions; its sole operative section eliminates the federal law and all amendments made by it.
The Robinson-Patman Act is a federal antitrust law that restricts certain forms of price discrimination in sales of goods. Repealing it would remove those statutory restrictions from the U.S. Code, potentially changing how manufacturers, wholesalers, distributors, and retailers structure pricing and discounts. The bill’s title suggests supporters view repeal as a way to preserve or expand prescription drug discounting, though the text itself applies broadly to the entire Act rather than only to pharmaceuticals.
Impact
If enacted, SB2099 would strike the Robinson-Patman Act and related amendments from federal law, removing a long-standing antitrust price-discrimination regime from Title 15 of the U.S. Code. That would affect businesses engaged in interstate commerce by reducing federal constraints on differential pricing, promotional allowances, and discounts. Although the bill is framed around prescription drug discounts, its legal effect would extend beyond pharmaceuticals to all covered commercial transactions historically regulated by the Robinson-Patman Act.
Sentiment
There is no recorded committee transcript or vote history provided, so there is no direct evidence of debate or formal support/opposition in the available materials. The bill’s title indicates a pro-repeal, pro-discounting policy rationale, likely appealing to supporters of lower drug prices and more flexible pricing practices. At the same time, because the bill would repeal an antitrust statute across the board, it would likely draw concern from those who favor maintaining protections against discriminatory pricing and market concentration.
Contention
The main point of contention is the scope of the repeal. Supporters are likely to emphasize that eliminating Robinson-Patman would make it easier to offer discounts, including in the prescription drug market, while critics may argue that the bill goes far beyond pharmaceuticals and removes a broader antitrust safeguard. Another likely dispute is whether repealing the Act would benefit consumers through lower prices or instead disadvantage smaller competitors by allowing larger firms to use aggressive pricing strategies.